ZA201303996B - Compositions and methods for treating amyloid plaque associated symptoms - Google Patents

Compositions and methods for treating amyloid plaque associated symptoms

Info

Publication number
ZA201303996B
ZA201303996B ZA2013/03996A ZA201303996A ZA201303996B ZA 201303996 B ZA201303996 B ZA 201303996B ZA 2013/03996 A ZA2013/03996 A ZA 2013/03996A ZA 201303996 A ZA201303996 A ZA 201303996A ZA 201303996 B ZA201303996 B ZA 201303996B
Authority
ZA
South Africa
Prior art keywords
compositions
methods
amyloid plaque
associated symptoms
treating amyloid
Prior art date
Application number
ZA2013/03996A
Other languages
English (en)
Inventor
Adam Eltorai
Jungsu Kim
David Holtzman
Hong Jiang
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of ZA201303996B publication Critical patent/ZA201303996B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA2013/03996A 2010-12-02 2013-05-31 Compositions and methods for treating amyloid plaque associated symptoms ZA201303996B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41906010P 2010-12-02 2010-12-02
US201161548542P 2011-10-18 2011-10-18
PCT/US2011/063121 WO2012075422A2 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Publications (1)

Publication Number Publication Date
ZA201303996B true ZA201303996B (en) 2015-10-28

Family

ID=46172597

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/03996A ZA201303996B (en) 2010-12-02 2013-05-31 Compositions and methods for treating amyloid plaque associated symptoms

Country Status (14)

Country Link
US (2) US20140037638A1 (enExample)
EP (1) EP2646053A4 (enExample)
JP (1) JP2014502276A (enExample)
KR (1) KR20140017513A (enExample)
CN (1) CN103338786A (enExample)
AU (1) AU2011336360A1 (enExample)
BR (1) BR112013013723A2 (enExample)
CA (1) CA2819679A1 (enExample)
MX (1) MX2013006116A (enExample)
NZ (1) NZ611614A (enExample)
RU (1) RU2013130002A (enExample)
SG (1) SG190952A1 (enExample)
WO (1) WO2012075422A2 (enExample)
ZA (1) ZA201303996B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
WO2017192711A1 (en) * 2016-05-03 2017-11-09 University Of South Florida Compositions and methods of modulating abeta protein
AU2017350947B2 (en) * 2016-10-28 2024-02-15 Washington University Anti-ApoE antibodies
JP7280238B2 (ja) * 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
AU2020282792B2 (en) * 2019-05-28 2025-12-04 Banner Health ApoE antibodies, fusion proteins and uses thereof
WO2023069892A1 (en) * 2021-10-19 2023-04-27 Short Jay M Conditionally active proteins for neurodegenerative diseases
AU2023399623A1 (en) * 2022-11-30 2025-07-03 Bio-Techne Corporation Natural killer cell engagers
WO2026019667A1 (en) * 2024-07-17 2026-01-22 Jn Biosciences Llc Trispecific antibodies for activation of immune cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142300C (en) * 1992-10-13 2005-08-23 Allen D. Roses Methods for detecting alzheimer's disease
WO2005051998A2 (en) * 2003-11-28 2005-06-09 Astrazeneca Ab Antibodies binding to a c-terminal fragment of apolipoprotein e
EP1736162A1 (en) * 2004-03-30 2006-12-27 Renomedix Institute Inc. Remedy for prion disease and method of producing the same
EP1991252A2 (en) * 2006-02-21 2008-11-19 Oklahoma Medical Research Foundation Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CA2791648A1 (en) * 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof

Also Published As

Publication number Publication date
KR20140017513A (ko) 2014-02-11
WO2012075422A2 (en) 2012-06-07
US20160355581A1 (en) 2016-12-08
CN103338786A (zh) 2013-10-02
EP2646053A4 (en) 2014-05-28
AU2011336360A1 (en) 2013-07-04
SG190952A1 (en) 2013-07-31
NZ611614A (en) 2015-07-31
EP2646053A2 (en) 2013-10-09
WO2012075422A3 (en) 2012-10-04
MX2013006116A (es) 2013-10-17
CA2819679A1 (en) 2012-06-07
JP2014502276A (ja) 2014-01-30
US20140037638A1 (en) 2014-02-06
BR112013013723A2 (pt) 2019-09-24
RU2013130002A (ru) 2015-01-10

Similar Documents

Publication Publication Date Title
IL263729A (en) Preparations and methods for removing biofilms
EP2655334A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
ZA201302625B (en) Methods and compositions for treating hemophilia b
ZA201303423B (en) Compositions and methods for treating myelofibrosis
ZA201404187B (en) Compositions and methods for treating dental conditions
WO2011049960A9 (en) Compositions and methods for the treatment of sinonasal disorders
IL215592A0 (en) Compositions and methods for the treatment of inflammation
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
PH12013500698A1 (en) Hair-mending compositions and associated methods
IL234829A0 (en) Methods and preparations for treating inflammation
ZA201307187B (en) Synergistic compositions and methods
IL231157A0 (en) Preparations and methods for the treatment of neurodegenerative diseases
IL231158A0 (en) Preparations and methods for the treatment of neurodegenerative diseases
ZA201203002B (en) Compositions and methods for treating inflammatory disorders
EP2480579A4 (en) METHODS OF TREATING INFLAMMATION
EP2590674A4 (en) COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
IL225483A0 (en) The compositions and methods for the treatment of neoplasia
IL232648A0 (en) Preparations and methods for treating glioma
EP2646053A4 (en) COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS ASSOCIATED WITH AMYLOIDER PLAQUE
IL253853A0 (en) Methods and preparations for the treatment or prevention of symptoms of hormonal changes
ZA201304353B (en) Remedial composition and treatment methods
IL223095A0 (en) Methods and compositions for treatment nf-kb-mediated and a7 integrin-suppressed diseases
SG10201510568WA (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
EP2461870A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD